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Background: who  is at risk and what is the outcome of lupus? 
Systemic lupus erythematosus (SLE or lupus for short) is a multisystem, autoimmune disease that can 
present in women or men at any age but is most common in women in the reproductive age group especially 
women of African-Caribbean and South Asian descent1. Lupus presents increasingly after the age of 40 in 
Europeans and affected nearly 1 in 1000 of the population in the UK in 20121. The mean age at diagnosis 
was 48.9 years1 but was lower in those of African ancestry 1. These patients of African origin are at increased 
risk of lupus nephritis which occurs in about one third of UK lupus patients. End-stage renal disease 
occurred in 20% of lupus nephritis patients in a UK cohort study.  The mean age at death was 40.3 years with 
an average of 7.5 years between death and development of lupus nephritis 2. Another UK cohort study 
showed that there is still an increased risk of premature death in women and men with lupus in general, with 
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a mean age of death of 53.7 years 3. Most deaths were due to infection or cardiovascular disease and active 
lupus rarely caused death in the UK3;4. In addition lupus causes considerable morbidity as it may present with 
slowly or rapidly progressive active disease that can lead to the accumulation of chronic damage if not 
promptly diagnosed, appropriately treated and regularly monitored 5;6.  
 
To optimise these aspects of management and to improve the outcome of this variable and potentially life-
threatening disease the British Society of Rheumatology (BSR) published a NICE-accredited guideline for 
the management of systemic lupus erythematosus in adults in 20187. The full guideline}8 is available open 
access online for reference and covers in detail the diagnosis, assessment, and monitoring of lupus and the 
treatment of mild, moderate and severe active lupus disease. The recommendations are evidence-based 
following an extensive literature review up to June 2015. The guideline does not cover the evidence for 
paediatric lupus as there is relatively little literature on paediatric lupus. The target audience includes 
rheumatologists and other clinicians such as nephrologists, immunologists and dermatologists, trainees in 
these specialties and emergency medicine, as well as GPs, clinical nurse specialists, and other allied health 
professionals involved in the care of adult lupus patients7;8.  
 
How does lupus present clinically? 
SLE can present with a large variety of clinical features affecting any system in the body, so making the 
diagnosis can be a challenging process9-11. Delays in diagnosis are well recognised and remain a concern12. 
Some of the most typical mild, moderate and severe features are shown in the Figure. It is important to 
ensure that the diagnosis of lupus is appropriate before considering treatment 10;11. Lupus should be 
considered particularly, but not exclusively, in individuals at increased risk of the disease from African, 
South Asian and Chinese backgrounds13. It is widely recognised that lupus causes fatigue, skin rashes often 
associated with photosensitivity, hair loss and inflammatory arthritis mainly in women. However it is 
important to remember that lupus can affect men as well. In fact in men it often results  in severe disease 
including renal involvement and more chronic scarring (damage) compared with women in many studies, 
possibly due to delayed diagnosis 3;4;14. Renal and neurological involvement cause a lot of morbidity and 
mortality 3;4. Constitutional (e.g. fever and lymphadenopathy) cardio-respiratory (e.g. pleurisy and 
pericarditis), gastrointestinal (e.g. gall bladder vasculitis) and hepatic (e.g. autoimmune hepatitis) features 
may occur in up to 60% of patients but are often not recognised as being due to lupus, and need to be 
distinguished from infection, drug side-effects and other co-morbid conditions including lymphoma8. Eye 
involvement, other than sicca symptoms, is rare but potentially sight-threatening and requires prompt referral 
to an experienced ophthalmologist15.  
 
Causes of lupus, drug-induced lupus and immunological manifestations 
The clinical features of acute lupus are mostly due to the formation of immune complexes involving 
autoantibodies that induce complement activation and consumption resulting in inflammatory processes that 
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affect a variety of organs. Thrombosis associated with anti-phospholipid antibodies may contribute to the 
pathogenesis in some patients5;9. The autoantibodies are produced as a result of a variety of mechanisms 
including defective clearance of apoptotic cells, excessive B cell activation and proliferation, altered T cell 
signalling and function, and changes in cytokine profiles with an increasing role for interferon-alpha in 
recent research 5;16. There is evidence for underlying genetic susceptibility involving an increasing number of 
loci (50-100 genes) and pathways with environmental triggers including infections, UV light, hormones such 
as estrogen, and cigarette smoking. Drug-induced lupus is also recognized and usually resolved in 
withdrawal of the offending drug, for example  tetracyclines, isoniazid, sulphonamides, propylthiouracil, 
hydralazine, procainamide, phenytoin  and anti-TNF therapy5;17;18. Anti-TNF may induce autoantibodies such 
as ANA without inducing lupus disease, however these drugs may also trigger full SLE in susceptible 
people. The importance of environmental influences is shown by the observation that only in about one in 
four twin pairs where one twin has SLE do both develop lupus over time. 
 
An autoantibody screen should be performed when there is a clinical suspicion of SLE. Most lupus patients 
are ANA positive (<95%). If ANA  is negative, there is a low clinical probability of the patient having SLE 
however a minority have anti-double stranded (ds)DNA or anti-Ro antibody positivity without ANA that will 
be found when assessed on clinical grounds by a specialist19.  ANA tests are not specific for the diagnosis of 
lupus and may occur in a variety of other conditions including Sjögren’s syndrome, systemic sclerosis, 
dermatomyositis, viral infections such as infectious mononucleosis and occur sometimes in patients with 
cancer11. The ANA test can become negative in treated patients and the results can vary with different 
assays. Anti-dsDNA and anti-Sm antibodies are rare in other conditions but are less sensitive than ANA 9;19-
21. Anti-dsDNA antibodies rise and complement C3 and C4 levels fall with active disease  and are useful in 
monitoring disease as well as diagnosis (Box 1)7;8.  
 
Anti-Ro and anti-La antibodies are associated with photosensitivity, subacute cutaneous lupus rashes, 
Sjögren’s syndrome and neonatal lupus syndrome including congenital complete heart block in babies11;22.  
Anti-RNP antibodies occur in overlap conditions such as mixed connective tissue disease with myositis and 
lung involvement11. Lupus patients should be tested for anti-phospholipid antibodies as this indicates a group 
at increased risk of arterial/venous thrombosis and adverse pregnancy outcomes such as 3 or more first 
trimester miscarriages, late pregnancy losses and pre-eclampsia before 34 weeks gestation 23;24. Confirmatory 
tests for antiphospholipid syndrome are positive lupus anticoagulant, anti-cardiolipin antibodies (IgG, IgM), 
and/or anti-beta-2 glycoprotein-1(IgG, IgM) antibodies on two occasions at least 12 weeks apart23;24. The 
lupus anticoagulant test is the most specific of the 3 tests and is associated with a higher positive predictive 
value. Triple positivity characterised by positive lupus anticoagulant, anticardiolipin, and anti-β2-
glycoprotein- I antibodies is associated with a cumulative incidence of thrombosis of 37.1% after 10 years 25. 
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Diagnosis of lupus and classification criteria 
When considering a diagnosis of SLE, a detailed clinical history and examination is required to identify 
clinical features supported by renal and haematological assessment. A low CRP with a raised ESR is typical 
of active lupus unless there is infection or effusions. According to the BSR guidelines for lupus7;8 the 
diagnosis of SLE requires a combination of clinical features and the presence of at least one relevant 
immunological abnormality as discussed above. A positive ANA occurs in approximately 5% of adults and 
has poor diagnostic value in the absence of clinical features of lupus or other autoimmune disease. The 
American College of Rheumatology (ACR) 26;27 and Systemic Lupus International Collaboration Clinics 
(SLICC) 28 (table 1) classification criteria are not diagnostic criteria but may be helpful when considering the 
diagnosis, however they do not cover all the possible clinical manifestations of lupus. 
 
Based on the ACR( previously the American Rheumatism Association) revised criteria for SLE published in 
198226 and the 1997 modification27, a patient may be classified as having SLE if they have had 4 or more of 
11 criteria at any time. However, not all patients with these criteria have lupus and not all patients diagnosed 
clinically with lupus have 4 or more of these criteria. The SLICC group devised alternative classification 
criteria for lupus to overcome these and related issues (Table 1) 28. The critical difference is that they 
introduced a requirement for at least one clinical and one immunological criterion and two others from an 
expanded list of items compared to the traditional ACR criteria27. Biopsy proven lupus nephritis in the 
presence of ANA or anti-dsDNA antibodies may also be classified as lupus without the need for other 
criteria28. Low complement (C3 and/or C4) are included in the serological criteria as they reflect complement 
consumption due to formation of immune complexes in active lupus disease. Although the SLICC criteria 
are more intuitive and include evidence for the immunopathological basis of lupus, diagnosis should not be 
restricted to patients that meet these classification criteria. According to the BSR guidelines for SLE7;8 a 
diagnosis of SLE can also be made in the presence of other lupus manifestations in the appropriate 
serological context and should not be made if features are better explained by an alternative diagnosis (such 
as a different systemic autoimmune disease, infection or cancer).  
 
Clinical assessment of SLE patients 
Clinical assessment should include detailed history and review of systems, ideally with full clinical 
examination including urinalysis in order to determine whether symptoms and signs may be due to lupus 
disease activity, accumulated damage due to the effects of the disease or its treatment such as lung fibrosis or 
atherosclerosis, drug toxicity and/or the presence of co-morbidity. Fatigue is very common but non-specific 
as it can be hard to distinguish whether the cause is lupus itself or if there is another autoimmune condition 
such as hypothyroidism, anaemia due to iron deficiency (not haemolysis from lupus), fibromyalgia which 
can co-exist with lupus in up to 30% of patients or physical deconditioning.  
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Haematological, biochemical, immunological and imaging tests help to determine whether new disease 
features are due to active inflammation, thrombosis or co-morbidity such as infection. This is an important 
distinction as this will affect the need for specialist review and future treatments. Antiphospholipid 
antibodies are associated with thrombotic events, damage and adverse outcomes in pregnancy and should be 
re-evaluated prior to pregnancy or surgery, and when there is a new severe manifestation or vascular event 
even if the tests were negative previously. Patients may need referral for skin or renal biopsies to ensure that 
lupus is the cause of the manifestations before starting definitive treatment. Advice about further assessment 
and treatment should be sought from relevant hospital specialists such as rheumatologists, nephrologists, 
haematologists and specialist obstetricians depending on the extent of disease activity and whether planning 
pregnancy or not. Mild disease activity is clinically stable lupus with no life-threatening organ involvement 
(see Figure). Patients with moderate disease activity have more serious manifestations requiring more intense 
immunosuppression and severe disease is defined as organ or life threatening. With an increase in disease 
activity (termed lupus flare) it can be helpful to consider the likely triggers such as exposure to sunlight, 
concurrent or recent infection, hormonal changes, and any recent drug change as this will guide further 
investigation, current treatment change and future  monitoring.  
 
 
Monitoring of SLE patients 
Patients with lupus should be monitored regularly for disease features, drug toxicity and co-morbidities7;8.  
Depending on the complexity of the disease and the drug therapy this may need to be performed by a 
hospital specialist e.g. rheumatologist, nephrologist, dermatologist or by the GP or shared care between the 
relevant teams. Patients with active disease should be reviewed at least every 1-3 months with blood 
pressure, urinalysis, renal function, liver function tests, anti-dsDNA antibodies, complement levels and full 
blood count with further tests as necessary (box 1). ESR is usually high and CRP low with active lupus so an 
increase in CRP should prompt infection screen. Patients with stable low disease activity or in remission may 
be reviewed less frequently such as 6 to 12 monthly, As lupus disease activity and complications such as 
atherosclerotic disease, infection and drug side-effects can develop at any time, patients should be monitored 
indefinitely7;8. Anti-Ro and La antibodies are associated with neonatal lupus (including congenital heart 
block) and should be checked prior to pregnancy but are not helpful for assessing disease activity (box 1). A 
detailed guide to the interpretation of haematological, renal and other biochemical parameters is included in 
the text of the BSR guidelines for the management of lupus and is available online8.  
 
Patients with lupus are at increased risk of infection, atherosclerotic disease, malignancy, osteoporosis and 
avascular necrosis. Patients should be screened for modifiable risk factors including hypertension, 
dyslipidaemia, diabetes, high body mass index and smoking annually7;8. They should have their vaccination 
status reviewed and be immunised as appropriate for example against influenza and pneumococcal 
pneumonia if they are on immunosuppressants (Table 2). Complications of lupus including chronic fatigue, 
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cardiovascular risk, osteoporosis, infection, and cancer risk should be managed according to national and 
international guidelines7;8. 
 
Treatment of  SLE 
Until recently only prednisolone and hydroxychloroquine were licensed for lupus5. There were relatively few 
trials until the last 15 years but in  2011, belimumab became the first drug to be licensed for the treatment of 
active lupus for over 50 years7;29;30. Much of the evidence supporting the use of drug therapies off-license in 
lupus comes from observational studies. This evidence is reviewed in the BSR guideline for the management 
of SLE which divides the treatment of lupus in to 3 sections covering mild, moderate and severe lupus7;8. 
(Figure). There is only summary advice about the use of drugs in the management of pregnant lupus patients 
as there is already a BSR guideline on the use of drugs in rheumatic diseases in pregnancy and breast-
feeding31;32. 
 
High factor UV-A and UV-B sunscreen are strongly recommended in the treatment and prevention of  UV 
radiation-induced cutaneous lesions supported by good evidence and there is some evidence that this strategy 
prevents other lupus manifestations.  Patients should be advised about sun avoidance and the use of 
protective clothing7;8. There is high quality evidence for the management of mild lupus using the disease 
modifying drugs hydroxychloroquine and methotrexate. These drugs reduce the need for corticosteroids7;8. 
Prednisolone doses up to 7.5mg/day may be required for maintenance therapy but topical preparations for 
cutaneous manifestations and intra-articular injections for arthritis are preferred although there is less 
evidence for their use. Short courses of non-steroidal anti-inflammatory drugs (NSAIDs) may be used for 
symptomatic benefit but the evidence is weak and the risks are considerable especially in patients with renal 
disease in whom they are contra-indicated7;8. 
 
The management of moderate lupus requires specialist advice and will usually involve the use of 
immunosuppressive, steroid sparing drugs such as azathioprine, mycophenolate mofetil, calcineurin 
inhibitors (ciclosporin and tacrolimus) or methotrexate with corticosteroids, in addition to 
hydroxychloroquine and avoidance of UV radiation7;8.  The aim is to reduce disease activity, prevent further 
flares and lower the risk of damage accrual due to disease and corticosteroids in patients with features such as 
arthritis, cutaneous disease, serositis, vasculitis, or cytopaenias not controlled by hydroxychloroquine. Initial 
doses of prednisolone up to 0.5 mg/kg/day or the use of intramuscular or intravenous doses of 
methylprednisolone may be required to control active disease but prednisolone should be reduced steadily to 
a baseline of 7.5mg/day or less and withdrawn later if possible7;8. For patients that are refractory to these 
drugs, patients should be discussed with and/or seen by a regional specialist lupus centre. The biologic drugs 
belimumab and rituximab may be considered if the patients meet the appropriate criteria for these drugs7;8: 
NICE guidance for the use of belimumab in active autoantibody-positive SLE in adults published in 2016 
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(https://www.nice.org.uk/guidance/TA397) or the   NHS England 2013 interim clinical commissioning policy 
statement for rituximab in adult SLE patients (http://www.england.nhs.uk/wp-
content/upSOAds/2013/09/a13-psa.pdf).  
 
Organ or life-threatening severe lupus disease, for example lupus nephritis or neuropsychiatric lupus, requires 
treatment by a specialist with intensive immunosuppression followed by prolonged maintenance therapy to 
prevent relapse7;8. This usually involves intravenous methylprednisolone initially but may consist of high 
dose oral prednisolone (up to 1 mg/kg/day)) to induce remission with mycophenolate mofetil or 
cyclophosphamide, followed by steroid taper over several months. The biological therapies belimumab and 
rituximab are considered if patients fail conventional immunosuppressive drugs due to inefficacy or 
intolerance as described above.  Intravenous immunoglobulin and plasmapheresis are rarely used.  In some 
cases there may be a thrombotic component to the clinical features that requires anticoagulation, The 
evidence is best for the management of lupus nephritis, weaker for neuro-psychiatric disease and is sparse for 
other specific organ-specific manifestations7;8.   
Organisation of care for SLE patients 
GPs should refer patients suspected of suffering from lupus to a physician with experience of managing 
lupus so that they can confirm the diagnosis, assess the level of disease activity and provide advice on 
treatment and monitoring of lupus, its complications and side-effects of therapy. Immunosuppressive 
therapies are challenging to use in patients with lupus due to the risk of adverse events including infection, 
difficulties with attribution of cytopenias to lupus or cytotoxic drugs, and the need to distinguish disease 
activity from damage and co-morbid conditions8. Shared care agreements may be put in place once patients 
are established and stable on therapy. SLE patients should have access to a multi-disciplinary team including 
a variety of specialists including rheumatologists, nephrologists, dermatologists, haematologists, 
cardiologists, chest physicians, neurologists, obstetricians, nurse specialists, physiotherapists, as well as 
podiatrists and occupational therapists working as part of collaborative clinical networks involving regional 
specialist centres, local hospitals and GPs8. Patients should be monitored to ensure that they achieve a low 
level of disease activity if not remission33;34 using hydroxychloroquine, immunosuppressants and the 
minimum amount of corticosteroids, in order to reduce accumulating damage from the disease and its 
treatment33. If drug treatment is not working within the expected time frame, it is important to consider 
adherence to treatment and to get patients reviewed so that drug therapy can be optimised to promote disease 
control and to reduce the risk of further morbidity and premature death..  
 
It is important for GPs to be involved in ensuring use of sunscreen and sun avoidance, adequate vitamin D3 
intake given the inability to synthesise vitamin D in the skin without UV light exposure, weight control, 
exercise, not smoking and other measures to reduce atherosclerotic and osteoporosis risk factors, as well as 
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cancer screening, contraception and pregnancy planning when the disease is under good control on 
appropriate treatment for conception (box 2)8. 
. 
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Table 1: Clinical and Immunologic Criteria Used in the SLICC Classification Criteria for SLE28  
 
Clinical Criteria 
1. Acute cutaneous lupus including: 
            lupus malar rash  (do not count if malar discoid) 
bullous lupus  
toxic epidermal necrolysis variant of SLE  
maculopapular lupus rash  
photosensitive lupus rash  
in the absence of dermatomyositis  
or subacute cutaneous lupus  
(nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, 
although occasionally with postinflammatory dyspigmentation or telangiectasias). 
2. Chronic cutaneous lupus including: 
            classical discoid rash  
localized (above the neck)  
generalized (above and below the neck)  
hypertrophic (verrucous) lupus  
lupus panniculitis (profundus)  
mucosal lupus  
lupus erythematosus tumidus  
chilblains lupus  
discoid lupus/lichen planus overlap  
3. Oral ulcers:  
                        palate 
buccal 
tongue 
or nasal ulcers 
in the absence of other causes, such as vasculitis, Behcet’s disease, infection (herpes viruses), inflammatory bowel 
disease, reactive arthritis, acidic foods 
4. Nonscarring alopecia (diffuse thinning or hair fragility with visible broken hairs) 
in the absence of other causes such as alopecia areata, drugs, iron deficiency and androgenic alopecia 
5. Synovitis involving two or more joints, characterized by swelling or effusion  
    or tenderness in 2 or more joints and thirty minutes or more of morning stiffness.   
6. Serositis 
typical pleurisy for more than 1 day   
  or pleural effusions 
 or pleural rub 
typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 day 
 or pericardial effusion 
 or pericardial rub 
 or pericarditis by EKG 
in the absence of other causes, such as infection, uremia, and Dressler’s pericarditis 
7. Renal 
Urine protein:creatinine ratio (or 24 hr urine protein) representing 500 mg of protein/24 hr 
   or 
Red blood cell casts 
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8. Neurologic 
 seizures 
 psychosis  
 mononeuritis multiplex  
  in the absence of other known causes such as primary vasculitis 
 myelitis  
 peripheral or cranial neuropathy  
  in the absence of other known causes such as primary vasculitis, infection, and diabetes mellitus 
 acute confusional state  
  in the absence of other causes, including toxic-metabolic, uremia, drugs 
9. Hemolytic anemia 
10. Leukopenia (< 4000/mm3 at least once)  
in the absence of other known causes such as Felty’s, drugs, portal hypertension 
 OR 
Lymphopenia (< 1000/mm3 at least once)  
in the absence of other known causes such as corticosteroids, drugs and infection 
11. Thrombocytopenia (<100,000/mm3) at least once  
in the absence of other known causes such as drugs, portal hypertension, TTP 
 
 
Immunologic Criteria 
 
1. ANA level above laboratory reference range 
2. Anti-dsDNA antibody level above laboratory reference range (or > 2 fold the laboratory reference 
range if tested by ELISA)  
3. Anti-Sm 
4. Antiphospholipid antibody:  any of the following 
lupus anticoagulant  
false-positive rapid plasma regain (RPR)  
medium or high titer anticardiolipin antibody level (IgG, IgM or IgA) 
anti-2 glycoprotein I (IgG, IgM or IgA) 
5. Low complement 
low C3  
low C4  
low CH50  
6. Direct Coombs’ test in the absence of hemolytic anemia 
 
* Patients can be classified as having SLE if they satisfy 4 of the clinical and immunological criteria 
including at least one clinical criterion and one immunologic criterion, OR if they have biopsy-proven 
nephritis compatible with SLE in the presence of ANAs or anti-dsDNA antibodies (68). 
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Table 2:  Modifiable risk factors to review at least annually 
Infection Vaccination status 
Cardiovascular disease Hypertension 
Dyslipidaemia 
Diabetes 
High BMI 
Smoking 
Malignancy Routine cancer screening as per national 
guidelines 
 
 
Box 1:  Measuring autoantibodies in patients with SLE 
• Increasing Anti-dsDNA antibody levels, and falling C3 and/or C4 complement levels are associated 
with disease flare. 
• ANA, anti-Sm and anti-RNP antibodies do not change with disease activity and should not be 
routinely measured. 
• Measure anti-Ro and anti-La in women planning pregnancy due to risk of congenital heart block (1-
2%). 
• Check lupus anticoagulant and anti-phospholipid antibodies at baseline and following i) a new 
vascular event, ii) prior to pregnancy, iii) following an adverse pregnancy outcome. 
 
Box 2: Pregnancy and SLE 
• Women with SLE should be referred for pre-pregnancy counselling. 
• Pregnancy can increase SLE disease activity and flare.  This risk is reduced if the disease is stable for 
at least 6 months prior to conception. 
• Anti-cardiolipin antibodies and lupus anticoagulant antibodies are associated with increased 
pregnancy loss, preterm birth and intrauterine growth restriction.  Specialist advice should be 
sought. 
• Prednisolone, azathioprine, hydroxychloroquine, cyclosporine, tacrolimus, low molecular weight 
heparin and low-dose aspirin are safe in pregnancy and breast feeding. 
• Methotrexate, leflunomide, cyclophosphamide, myophenolate mofetil and biological drugs 
(rituximab and belimumab) are not safe in pregnancy and should be stopped prior to conception.  
Seek specialist advice. 
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Figure:  Overview of the management of SLE 
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Dear Caroline 
  
We were very pleased with your article, please find the proofs attached. 
  
 I would be grateful if you could: 
* read and check the proofs carefully, particularly all data, the figure, tables, boxes and references 
* answer the questions raised at the reviewing and editing stages  
* get back to me with your amendments by 2pm Tues May 21. Please drop your corrections into a copy 
of this email and send it back to me.  
  
  
PAGE 17 
Editing queries 
Byline 
Please check that the details are correct for all authors yes 
  
Figure 1 
1 Please supply a reference for the diagram Original By JR for this 
2 Please obtain permission to reproduce this, if necessary, and supply a credit, if appropriate N/A 
  
GP reviewer’s queries 
Col 1, 2nd para 
‘End-stage renal disease occurred in 20% of lupus nephritis patients in a UK cohort study. The mean age at 
death’ for all patients with lupus nephritis was 40.3 years with an average of 7.5 years between the 
development of lupus nephritis and death.2 
 
Please rewrite to clarify meaning- done as above 
  
‘Another UK cohort study showed that there is still an increased risk of premature death in women and men 
with lupus in general, with a mean age of death in those that died of 53.7 years. 3  
  
This sentence is misleading: 382 patients were followed up for up to 21 years during which time 37 patients 
(9.7% of the cohort) died. Those who died had a mean age at death of 53.7 years. According to Lupus 
UK “most patients can anticipate a normal lifespan.” 
Please amend/rewrite to clarify- done as above- I assume that you do not want this expanded to both 
sentences provided by the reviewer. If you want the longer version suggest “In another UK cohort study, 
382 patients were followed up for up to 21 years during which time 37 patients (9.7% of the cohort) died. 
Those who died had a mean age at death of 53.7 years. 
  
Col 3, 2nd para 
‘Lupus causes fatigue, skin rashes often associated with photosensitivity, hair loss and inflammatory arthritis 
mainly in women. However it is important to remember that lupus can affect men as well. In men it often 
Comment [CG2]: This was actually 
only a study of lupus nephritis but I 
accept that this was not clear 
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results in severe disease including renal involvement and more chronic scarring (damage) compared with 
women in many studies, possibly due to delayed diagnosis. 3;4;14 Renal and neurological involvement 
cause considerable morbidity and mortality.3;4 Constitutional (e.g. fever and lymphadenopathy) cardio-
respiratory (e.g. pleurisy and pericarditis), gastrointestinal (e.g. gall bladder vasculitis) and hepatic (e.g. 
autoimmune hepatitis) features may occur in up to 60% of patients but are often not recognised as being 
due to lupus, and need to be distinguished from infection, drug side effects and other comorbid 
conditions including lymphoma.8’ Depression occurs in about 20% of lupus patients but is not usually 
caused directly by autoimmune disease mechanisms. 
  
A UK primary care study which used the Clinical Practice Research Database identified 1,426 incident cases 
of SLE (170 males and 1256 females). The most commonly reported symptoms prior to diagnosis were: 
musculoskeletal (arthritis/arthralgia in 58.6%, myalgia in 8.8%), mucocutaneous (41%, mostly 
unspecified, 3% maculopapular, 4% discoid) and neurological (depression 20.6%, psychosis 0.04%, 
seizures 3.1%). The median time from first musculoskeletal symptom to diagnosis was 26.4 months. 
(Nightingale et al BMJ Lupus 2016;4:issue 1). 
Thus from these findings depression appears to be a common presenting symptom whereas psychosis 
appears to be rare. 
1 Do the authors wish to comment on this? 
  
2 When making a diagnosis of major depression, GPs should consider whether it is associated with an 
underlying condition. I feel that the list of conditions which can present with, or be associated with, 
depression should include autoimmune rheumatic disorders such as SLE, rheumatoid arthritis and PMR. 
What do the authors think? 
Ed: Please only comment on the CPRD findings and answer the queries if you see fit as strictly 
speaking they are outside the scope of the brief 
  
PAGE 18 
Editing queries 
Note extra correction needed Table 1: references in title: ref28 is the correct reference source for this 
table. This table was reproduced in the BSR guidelines ref 8 (but ref 6 is not relevant at all). I 
would recommend only giving reference 28 at end of the main title of the table- if you want to 
reference the initial paragraph then it should be reference 28 again, as reference 8 reproduced the 
information from reference 28 and is not the source of this statement. 
Please check table 1 carefully 
Please add red circle before subacute cutaneous lupus rash. ( “in the absence of dermatomyositis” applied 
only to the photosensitive lupus rash). All the other items in this section are alternatives (hence the 
addition of “or” before the last item “subacute cutaneous lupus rash” (which is then described in more 
details as there are several forms of this rash, as listed in brackets appropriately). 
  
Also col 2 Immunological criteria 
4 Re anticardiolipin – IgG, IgM and IgA are specified but IgA is not mentioned in the text in this context 
(see p19, col 2, 5th para)  
Likewise for anti-beta2 glycoprotein 1 IgG, IgM and IgA are specified but IgA is not mentioned in the text in 
this context 
Please amend/clarify for consistency Suggest leaving as listed as this is the correct description of the SLICC 
classification criteria in table 1, as in ref 28 . IgA is not mentioned in the text as we did not discuss it in 
the BSR guidelines as not widely available in UK, and certainly not available to GPs. Also in the text we 
Comment [CG3]: I have contributed 
to a number of publications about 
neuropsychiatric disease in lupus by the 
SLICC group (multicentre inception cohort 
with over 1800 patients recruited by 
specialist centres within 6 months of 
diagnosis on average) and taken part in 
the EULAR neuropsychiatric management 
recommendations published in Annals of 
Rheumatic disease in the past. I agree 
that depression is more common that the 
conditions in the ACR and SLICC 
classification criteria  and we found about 
20% of lupus patients in the SLICC 
inception cohort study developed mood 
disorders, mostly depression but 
consensus is that it is rarely due to lupus 
autoimmunity and does not improve with 
immunosuppression in the absence of 
other lupus features warranting such 
treatment. I have added a short sentence 
about this. The Nightingale paper in Lupus 
Science and Medicine in 2017 
acknowledges that they were not able to 
deal with attribution to lupus and did not 
say that depression was due to 
autoimmune disease. There is not space 
to discuss this here in more detail but it is 
worth including as suggested. 
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quote and reference the source for the criteria for APS (refs 23 and 24) and they do not mention IgA 
either. I do not think this is worth explaining as most people will be aware that they cannot request these 
IgA tests but they may be available in some specialist centres if needed for patients requiring review at 
some national centres of excellence due to uncertainty about diagnosis or management. 
  
We have written out TTP as thrombotic thrombocytopenic purpura - is this correct? YES  
  
  
PAGE 19 
Editing queries 
Col 1 Causes and immunological manifestations 
Re anti-TNF should this be anti-TNF-alpha throughout? Yes that is correct (but it is the only version of anti-
TNF therapy available and usually just called anti-TNF therapy). 
  
GP reviewer’s queries 
Col 1, final para 
‘An autoantibody screen should be performed when there is a clinical suspicion of SLE. Most lupus patients 
are ANA positive (> 95%). If ANA  is negative, there is a low clinical probability of the patient having 
SLE however a minority have anti-double stranded (ds)DNA or anti-Ro antibody positivity without 
ANA that will be found when assessed on clinical grounds by a specialist19.  
  
98% of patients will have positive ANA and/or anti-dsDNA antibodies (BSR guideline). Is it appropriate, 
therefore, for GPs to use a negative ANA plus negative anti-dsDNA antibody result as a rule-out test for 
SLE? No – true it is very unlikely but not impossible because they can have cytoplasmic anti-Ro or other 
antibodies mentioned in the SLICC classification criteria (or even less often anti-phospholipid 
antibodies)- I do not think that needs adding to the manuscript. These are cases where a decision 
would need to be made as to whether a second opinion was needed or not depending on other blood 
results and clinical features (high esr/low crp/high IgG/cytopenias would all favour lupus). Also 
antibodies can change over time… 
  
PAGE 20 
Editing queries 
Table 2 and box 1 – please check carefully 
Do either the table or box need a reference? These are both based on text of BSR guideline but 
not exactly as presented there eg in table 2 : vaccination status and high BMI are not terms 
mentioned in the text of ref 8 and there was no such table like this (most but not all 
items/synonims included in a bigger table in ref 8). Box 1 is a summary of some of the 
recommendations and text in the BSR guideline but this exact format is not written there (but all 
information is in ref 8). 
  
Col 3, 4th para 
‘Patients should be screened…annually.’ Table 2 says at least annually – do you want to amend 
the text to be consistent with the table? Yes- good idea- at least annually in both places 
  
GP reviewer’s queries 
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Col 1, 1st para 
‘Fatigue is very common but non-specific as it can be hard to distinguish whether the cause is lupus 
itself or if there is another autoimmune condition such as hypothyroidism, anaemia due to iron 
deficiency (not haemolysis from lupus), fibromyalgia which can coexist with lupus in up to 30% 
of patients, depression and/or physical deconditioning.’ 
Fatigue may also be a symptom of depression. A recent meta-analysis found a high prevalence of 
depression and anxiety in SLE patients: 24% had major depression and 37% had anxiety. 
(Zhang et al BMC Psychiatry 2017;17:70). 
ED: As before only add a brief comment if you see fit - happy to add as suggested in red (comments 
about depression above and not going to include anxiety as less common problem than depression 
in other studies but agree it can occur- we have not got space to discuss management of all issues 
that can occur in lupus patients….) 
  
Col 2, 4th para 
‘With an increase in disease activity (termed lupus flare) it can be helpful to consider triggers such as 
sunlight, concurrent or recent infection, hormonal changes, surgery and any recent drug change as this 
will guide further investigation, treatment and future monitoring.’  
I feel that this list of causes of a lupus flare should include surgery. What do the authors think? Happy to add 
as above but not that common unless drugs are stopped- an issue we have not got space to discuss here! 
  
Col 3, 3rd para 
‘Patients with lupus are at increased risk of infection, atherosclerotic disease, malignancy, osteoporosis and 
avascular necrosis.’  
  
How common is avascular necrosis? (A patient of mine had AVN in multiple joints.) Nil to 
change- well recognised but not as common as infection or atherosclerosis or osteoporosis 
GP reviewer’s queries  
PAGE 21  
Col 1, 2nd para 
  
‘Prednisolone doses up to 7.5mg/day may be required for maintenance therapy but topical preparations for 
cutaneous manifestations and intra-articular injections for arthritis are preferred although there is less 
evidence for their use.’ 
1 I think it is important to keep steroid use to a minimum to reduce the risk of avascular necrosis.  
What do the authors think? We say this later - NIL to add 
  
2 How common is it for SLE patients to develop other autoimmune conditions? (An SLE patient of mine 
developed myasthenia gravis.) Nil to add - we mention looking for other autoimmune conditions in the 
context of fatigue eg hypothyroidism (much more common than myasthenic gravis but about 15% 
develop at least one other autoimmune disease)- no space to discuss in detail.   
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Organisation of care for SLE patients 
‘SLE patients should have access to a multidisciplinary team including a variety of specialists including 
rheumatologists, nephrologists, dermatologists, haematologists, cardiologists, chest physicians, 
neurologists, obstetricians, nurse specialists, physiotherapists, as well as podiatrists and occupational 
therapists and clinical psychologists working as part of collaborative clinical networks involving regional 
specialist centres, local hospitals and GPs.8’  
  
In view of the high prevalence of anxiety and depression among SLE patients, plus rarer neuropsychiatric 
complications including psychosis, do the authors think the multidisciplinary team should include a 
clinical psychologist or psychiatrist? Agree that this was an omission- wish we had more access to 
clinical psychologists for lupus. Psychiatrists along with all other specialities not mentioned are needed 
less often and we could list all specialities…. If we could get all newly diagnosed patients to see a 
clinical psychologist we probably would not have to deal with as much depression, chronic non-specific 
pain like FM, fatigue etc…. 
  
PAGE 21 
Editing queries 
Competing interests 
Please check details and clarify whether John Reynolds has any competing interests - all correct and JR has 
NONE 
  
PAGES 21/22 
Please check all references carefully 
Correct page 19 middle column  3rd para end should be 23,24 not 23,2 (after gestation) 
Correct page 19 right column 3rd para reference after table 1,p18 should be 28 not 2. 
 
NB we have taken the respective (web) references for the 2 biologics out of the body copy of the text and 
added them to the ref section as refs 33 and 34. However the link to the NHS England document (now 
ref 34) does not work so please supply a correct version for this reference 
 
 Ref 34 = https://www.england.nhs.uk/wp-content/uploads/2013/09/a13-psa.pdf 
 
Useful information box 
 
 
Do you wish to add any details of professional bodies, charities or support groups that provide evidence-
based information for healthcare professionals and/or patients? 
  
Yes ! Please add:   
 
British Society for Rheumatology guidelines https://www.rheumatology.org.uk/practice-quality/guidelines 
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Lupus UK the national charity for people affected by lupus https://www.lupusuk.org.uk/ 
 
Versus Arthritis information on lupus 
https://www.arthritisresearchuk.org/shop/products/publications/patient-
information/conditions/lupus.aspx  
 
 
 
